

3
4 **Mitochondrial respiratory states and rates**

5
6 Gnaiger Erich et al (MitoEAGLE Task Group)*

7
8 Corresponding author: Erich Gnaiger

9 *Chair COST Action CA15203 MitoEAGLE – <http://www.mitoeagle.org>*

10 *Department of Visceral, Transplant and Thoracic Surgery, D. Swarovski Research Laboratory,*

11 *Medical University of Innsbruck, Innrain 66/4, A-6020 Innsbruck, Austria*

12 *Email: mitoeagle@i-med.ac.at; Tel: +43 512 566796, Fax: +43 512 566796 20*

13
14 Running title: Mitochondrial states and rates

15
16 **As the knowledge base and importance of mitochondrial physiology to evolution, health, and**
17 **disease expands, the necessity for harmonizing the terminology concerning mitochondrial**
18 **respiratory states and rates has become increasingly apparent. The chemiosmotic theory**
19 **establishes the mechanism of energy transformation in oxidative phosphorylation (OXPHOS) and**
20 **provides the theoretical foundation of mitochondrial physiology and bioenergetics. We follow**
21 **guidelines of the International Union of Pure and Applied Chemistry (IUPAC) on terminology,**
22 **extended by considerations of mitochondrial respiratory control, metabolic flows and fluxes. The**
23 **OXPHOS-capacity is respiration measured at kinetically-saturating concentrations of ADP and**
24 **inorganic phosphate. The oxidative electron transfer-capacity reveals the possible limitation of**
25 **OXPHOS-capacity mediated by the phosphorylation-pathway and is measured as noncoupled**
26 **respiration at optimum concentrations of external uncouplers. LEAK-respiration is the**
27 **intrinsically uncoupled oxygen consumption, compensating mainly for ion leaks — particularly**
28 **the proton leak — and studied in the absence of ADP or by inhibition of the phosphorylation-**
29 **pathway. Uniform standards for evaluation of respiratory states and rates will ultimately**
30 **contribute to reproducibility between laboratories and thus support the development of databases**
31 **of mitochondrial respiratory function in species, tissues, and cell types. Clarity of concept and**
32 **consistency of nomenclature facilitate effective transdisciplinary communication, education, and**
33 **ultimately further discovery.**

34
35 *Keywords:* Mitochondrial respiratory control, coupling control; mitochondrial preparations;
36 protonmotive force; uncoupling; oxidative phosphorylation: OXPHOS; electron transfer: ET; electron
37 transfer system: ETS; proton leak, ion leak and slip compensatory state: LEAK; residual oxygen
38 consumption: ROX; State 2; State 3; State 4; normalization; flow; flux; oxygen: O₂

39
40
41 **Harmonization of nomenclature**

42
43 Mitochondria are essential cellular, membrane-enclosed organelles that perform a large range of
44 functions critical for cell viability. Their best-known function is to synthesize adenosine triphosphate
45 (ATP) via oxidative phosphorylation (OXPHOS), but they also have important functions related to
46 cellular metabolism and cell-signalling. This importance has led to a large and increasing body of
47 research devoted to better understanding mitochondrial respiratory function. However, the
48 dissemination of fundamental knowledge and implementation of novel discoveries require
49 communication with a commonly understood terminology. Reproducibility of experimental procedures
50 also depends on strictly-defined conditions and harmonization of shared research protocols.
51 Unfortunately, a consensus on nomenclature and conceptual coherence is currently missing in the
52 expanding field of mitochondrial physiology and bioenergetics. The use of sometimes vague,
53 ambiguous, or inconsistent terminology likely contributes to confusion, miscommunication, and the

54 conversion of valuable signals to wasteful noise. Thus, complementary to quality control a conceptual
55 framework is required to standardise and harmonise terminology and methodology.

56 To fill the current gap, this perspective aims to harmonize nomenclature and addresses the
57 terminology on coupling states and fluxes through metabolic pathways of aerobic energy transformation
58 in mitochondrial (mt) preparations. In an attempt to establish a transdisciplinary nomenclature, we
59 strive to incorporate a concept-driven terminology of bioenergetics with explicit, easily recognized
60 terms and symbols that define mitochondrial respiratory states and rates. The consistent use of terms
61 and symbols will facilitate transdisciplinary communication for quantitative modelling and data
62 repositories on bioenergetics and mitochondrial physiology.¹⁻³

64 Coupling in mitochondrial respiration

66 **Respiration and fermentation.** Aerobic respiration is the O₂ flux in (1) OXPHOS with catabolic
67 reactions leading to O₂ consumption coupled to phosphorylation of ADP to ATP, plus (2) O₂ consuming
68 reactions apart from OXPHOS. Coupling of electron transfer (ET) to ADP→ATP phosphorylation is
69 mediated by vectorial translocation of protons across the mitochondrial inner membrane (mtIM). Proton
70 pumps generate or utilize the electrochemical protonmotive force, *pmF* (Fig. 1). The *pmF* is the sum of
71 two partial forces, the electric force (electric potential difference) and chemical force (proton chemical
72 potential difference, related to ΔpH).^{4,5} Cell respiration is thus distinguished from fermentation: (1)
73 Compartmental coupling in vectorial OXPHOS^{4,5} contrasts to substrate-level phosphorylation in
74 fermentation without utilization of O₂. (2) Redox balance is maintained in aerobic respiration by O₂ as
75 the electron acceptor supplied externally, whereas fermentation is characterized by internal electron
76 acceptors formed in intermediary metabolism (Fig. 1a).

78 **Respiratory states and respiratory capacity.** Cell membranes include organellar membranes and the
79 plasma membrane, which separates the intracellular milieu from the extracellular environment (Fig. 1a).
80 The plasma membrane consists of a lipid bilayer with embedded proteins and attached organic
81 molecules that collectively control the selective permeability of ions, organic molecules and particles,
82 limiting the passage of many water-soluble mitochondrial substrates and inorganic ions. Such limitations
83 are overcome in mitochondrial preparations: plasma membranes are removed or selectively
84 permeabilized, while mitochondrial structural and functional integrity is maintained⁶. In mt-
85 preparations, extramitochondrial concentrations of fuel substrates, ADP, ATP, inorganic phosphate (P_i),
86 and cations including H⁺ can be controlled to determine mitochondrial respiratory function under a set
87 of conditions defined as coupling control states (Tab. 1). In substrate-uncoupler-inhibitor titration
88 (SUIT) protocols, substrate combinations and specific inhibitors of ET-pathway enzymes are used to
89 obtain defined pathway control states^{7,8} (Fig. 1b). Pathway and coupling control states are
90 complementary, since mt-preparations depend on (1) an exogenous supply of pathway-specific fuel
91 substrates and O₂, and (2) exogenous control of phosphorylation⁹.

92 Reference respiratory states are established with kinetically-saturating substrate concentrations
93 for analysis of mitochondrial respiratory capacities. These delineate — comparable to channel capacity
94 in information theory¹⁰ — the upper boundary of O₂ consumption rates. Intracellular conditions in living
95 cells deviate from these experimental states. Further information is obtained in kinetic studies of flux as
96 a function of fuel substrate concentration, [ADP], or [O₂] in the range between kinetically-saturating
97 concentrations and anoxia¹¹.

99 **Phosphorylation.** The term phosphorylation is used generally in many contexts, *e.g.*, protein
100 phosphorylation. Phosphorylation in the context of OXPHOS is defined as phosphorylation of ADP by
101 P_i to form ATP, coupled to oxidative electron transfer (Fig. 1c,d). The ET- and phosphorylation-
102 pathways comprise coupled components of the OXPHOS-system. P/O is the ratio of P_i to atomic oxygen
103 consumed⁹. The symbol, P», is introduced here as more discriminating and specific than P (Fig. 1c).
104 The symbol P» indicates the endergonic (uphill) direction ADP→ATP, and likewise P« the
105 corresponding exergonic (downhill) hydrolysis ATP→ADP (Fig. 2). *J_{P»}* and *J_{P«}* are the corresponding
106 fluxes of ADP phosphorylation and ATP hydrolysis, respectively. P» refers mainly to phosphorylation
107 driven by proton translocation (Fig. 1d),¹² but may also involve substrate-level phosphorylation in the
108 mitochondrial matrix (succinyl-CoA ligase, monofunctional C1-tetrahydrofolate synthase), cytosol
109 (phosphoglycerate kinase and pyruvate kinase), or both (phosphoenolpyruvate carboxykinase isoforms

110 1 and 2). Kinase cycles are involved in intracellular energy transfer and signal transduction for regulation
 111 of energy flux ¹³.

112

113

Respiratory coupling control states: concept and nomenclature

114

115

Concept-driven terminology. Respiratory control refers to the ability of mitochondria to adjust O₂ flux
 116 in response to external control signals by engaging various mechanisms of control and regulation¹⁴.
 117 Respiratory control is monitored in mt-preparations under conditions defined as respiratory states,
 118 preferentially under near-physiological conditions of temperature, pH, and medium ionic composition.
 119 When phosphorylation of ADP to ATP is stimulated or depressed, an increase or decrease is observed
 120 in electron transfer measured as O₂ flux in respiratory coupling states of intact mitochondria ('controlled
 121 states' in the classical terminology of bioenergetics). Alternatively, coupling of electron transfer with
 122 phosphorylation is diminished by uncouplers, which eliminates control by P_» and increases respiratory
 123 rate (noncoupled or 'uncontrolled state'; Tab. 1).

124

Coupling efficiency is diminished by intrinsic and extrinsic uncoupling. Uncoupling of
 125 mitochondrial respiration is a general term comprising diverse mechanisms. Differences of terms —
 126 uncoupled *vs.* noncoupled — are easily overlooked, although they relate to different meanings of
 127 uncoupling (Tab. 2).

128

To extend the classical nomenclature on mitochondrial states (State 1 to 5) ¹⁵ by a concept-driven
 129 terminology that explicitly incorporates information on the meaning of respiratory states, the
 130 terminology must be general and not restricted to any particular experimental protocol or mitochondrial
 131 preparation ¹⁶. Standard respiratory coupling states are obtained while maintaining a defined ET-
 132 pathway state with constant fuel substrates and inhibitors of specific branches of the ET-pathway. The
 133 focus of concept-driven nomenclature is primarily the theoretical *why*, along with clarification of the
 134 experimental *how* ¹⁷.

135

In the three coupling states — LEAK, OXPHOS, and ET — the corresponding respiratory rates
 136 are abbreviated as *L*, *P*, and *E*, respectively (Fig. 2a). The *pmF* is *maximum* in the LEAK-state of coupled
 137 mitochondria, driven by LEAK-respiration at a minimum back-flux of cations to the matrix
 138 compartment, *high* in the OXPHOS-state when it drives phosphorylation, and *low* in the ET-state when
 139 uncouplers short-circuit the proton cycle (Tab. 1).

140

141

LEAK-state - Fig. 2b. The LEAK-state is the state of mitochondrial respiration when O₂ flux mainly
 142 compensates for ion leaks in the absence of ATP synthesis, at kinetically-saturating concentrations of
 143 O₂ and respiratory fuel substrates. Stimulation of phosphorylation is prevented by (1) absence of ADP
 144 and ATP; (2) maximum ATP/ADP ratio (State 4); or (3) inhibition of the phosphorylation-pathway with
 145 inhibitors of F₁F₀-ATPase (oligomycin; Omy) or adenine nucleotide translocase (carboxyatractyloside;
 146 Tab. 1). The chelator EGTA is added to mt-respiration media to bind free Ca²⁺, thus limiting cation
 147 cycling. LEAK-respiration is the intrinsically uncoupled O₂ consumption without addition of
 148 uncouplers. The LEAK-rate is a function of respiratory state, hence it depends on (1) the barrier function
 149 of the mtIM ('leakiness'), (2) the electrochemical potential differences and concentration differences
 150 across the mtIM, and (3) the H⁺/O₂ ratio of the ET-pathway (Fig. 1b).

151

State 4 is a LEAK-state after depletion of ADP ¹⁵. O₂ flux in State 4 overestimates LEAK-
 152 respiration if ATP hydrolysis activity recycles ATP to ADP, $J_{P«}$, which stimulates respiration coupled
 153 to phosphorylation, $J_{P»} > 0$. Inhibition of the phosphorylation-pathway by oligomycin ensures that $J_{P»} =$
 154 0 (State 4o; Tab. 1).

155

156

OXPHOS-state - Fig. 2c. At any given ET-pathway state, the OXPHOS-state establishes conditions to
 157 measure OXPHOS-capacity as a reference, at kinetically-saturating concentrations of O₂, as well as
 158 respiratory fuel and phosphorylation substrates. Respiratory OXPHOS-capacities, *P*, are related to ADP-
 159 phosphorylation capacities by the ATP yield per O₂ (Fig. 1c).

160

The OXPHOS-state is compared with State 3, which is the state stimulated by addition of fuel
 161 substrates while the ADP concentration in the preceding State 2 (see below) is still 'high' and supports
 162 coupled energy transformation in isolated mitochondria in a closed respirometric chamber ¹⁵. Repeated
 163 ADP titrations re-establish State 3. Starting at experimental O₂ concentrations, c_{O_2} , of air-saturation (193
 164 or 238 μM O₂ at 37 °C or 25 °C and sea level at 1 atm or 101.32 kPa, and an oxygen solubility of
 165 respiration medium at 0.92 times that of pure water) ¹⁸, the added ADP concentrations must be low

166 enough (typically 100 to 300 μM) to allow phosphorylation to ATP without O_2 depletion during the
 167 transition to State 4. In contrast, kinetically-saturating ADP concentrations are usually 10-fold higher
 168 than 'high ADP' (e.g., 2.5 mM) supporting OXPHOS capacity in isolated mitochondria ¹¹.

169
 170 **Electron transfer-state - Fig. 2d.** The ET-state is defined as the *noncoupled* state with kinetically-
 171 saturating concentrations of O_2 and respiratory substrate, and optimum exogenous uncoupler
 172 concentration for maximum O_2 flux (ET-capacity). Uncouplers are weak lipid-soluble acids that
 173 function as protonophores. These disrupt the barrier function of the mtIM and thus short-circuit the
 174 protonmotive system, functioning like a clutch in a mechanical device. As a consequence of the nearly
 175 collapsed *pmF*, the driving force is insufficient for phosphorylation and $J_{P_s} = 0$. The most frequently
 176 used uncouplers are carbonyl cyanide *m*-chloro phenyl hydrazone (CCCP), carbonyl cyanide *p*-
 177 trifluoromethoxyphenylhydrazone (FCCP), or dinitrophenol (DNP). Stepwise titration of uncouplers
 178 stimulates respiration up to or above the level of O_2 consumption rates in the OXPHOS-state; respiration
 179 is inhibited, however, above optimum uncoupler concentrations ⁵.

180 The abbreviation State 3u is occasionally used to indicate the state of respiration after titration of
 181 an uncoupler, without sufficient emphasis on the fundamental difference between OXPHOS-capacity
 182 (*well-coupled* with an endogenous uncoupled component) and ET-capacity (*noncoupled*; Fig. 2a).

183
 184 **ROX-state versus anoxia.** The state of residual O_2 consumption, ROX, is not a coupling state. The rate
 185 of residual oxygen consumption, *Rox*, is defined as O_2 consumption due to oxidative reactions measured
 186 after inhibition of ET with antimycin A alone or in combination with rotenone and malonic acid.
 187 Cyanide and azide inhibit not only CIV but also catalase and several peroxidases, whereas AOX is not
 188 inhibited (Fig. 1b). *Rox* represents a baseline to correct respiration: *Rox*-corrected *L*, *P* and *E* are not
 189 only lower than total fluxes, but also change the flux control ratios *L/P* and *L/E*. *Rox* is not necessarily
 190 equivalent to non-mitochondrial respiration, considering O_2 -consuming reactions in mitochondria that
 191 are not related to ET — such as O_2 consumption in reactions catalyzed by monoamine oxidases,
 192 monooxygenases (cytochrome P450 monooxygenases), dioxygenases (trimethyllysine dioxygenase),
 193 and several hydroxylases.

194 In the nomenclature of Chance and Williams, State 2 is induced by titration of ADP before
 195 addition of fuel substrates ^{15,19}. ADP stimulates respiration transiently on the basis of endogenous fuel
 196 substrates resulting in phosphorylation of a small portion of the added ADP. State 2 is then a ROX state
 197 at minimum respiratory activity after exhaustion of endogenous fuel substrates. State 5 'may be obtained
 198 by antimycin A treatment or by anaerobiosis' ¹⁵. These definitions give State 5 two different meanings:
 199 ROX or anoxia.

200 Anoxia is induced after exhaustion of O_2 in a closed respirometric chamber. Diffusion of O_2 from
 201 the surroundings into the aqueous solution is a confounding factor potentially preventing complete
 202 anoxia ¹¹.

203

204 Rates and SI units

205

206 The term *rate* is not adequately defined to be useful for reporting data. A rate can be (1) an extensive
 207 quantity ¹, termed *flow*, *I*, when expressed per chamber (instrumental system) or per countable, non-
 208 divisible *object* (number of cells, organisms, 'in-dividuals'); or (2) a size-specific quantity, termed *flux*,
 209 *J*, when expressed per volume or mass ² (Fig. 3).

210 Different units are used to report the O_2 consumption rate, OCR. SI units provide the common
 211 reference with appropriately chosen SI prefixes ¹. Although volume is expressed as m^3 using the SI base
 212 unit, the liter [dm^3] is a conventional unit of volume for concentration and is used for most solution
 213 chemical kinetics. Constants for conversion to SI units are summarized in Tab. 3.

214

215 Normalization of rate per system

216

217 **Flow: per chamber.** The instrumental system (chamber) is part of the measurement instrument,
 218 separated from the environment as an isolated, closed, open, isothermal or non-isothermal system.
 219 Analyses are restricted to intra-experimental comparison of relative differences, when reporting O_2
 220 flows per respiratory chamber, I_{O_2} [$\text{nmol}\cdot\text{s}^{-1}$] (Fig. 3).

221
 222 **Flux: per chamber volume.** System volume-specific O₂ flux, J_{V,O_2} (per liquid V of the instrumental
 223 chamber [L]), is of methodological interest in relation to the instrumental limit of detection. J_{V,O_2}
 224 increases in proportion to sample concentration in the chamber. At an O₂ flow of 100 amol·s⁻¹·cell⁻¹ and
 225 a cell concentration of 10⁹ cells·L⁻¹ (10⁶ cells·mL⁻¹), J_{V,O_2} is 100 nmol·s⁻¹·L⁻¹ (100 pmol·s⁻¹·mL⁻¹). J_{V,O_2}
 226 should be independent of the chamber volume at constant sample concentration. There are practical
 227 limitations to increasing the sample concentration in the chamber, when one is concerned about
 228 crowding effects and instrumental time resolution.

229

230 Normalization of rate per sample

231

232 **Flow: per object.** The oxygen flow per countable object, $I_{O_2/NX}$, is I_{O_2} divided by the number of objects
 233 in the chamber, N_X [x]. The oxygen flow per cell, $I_{O_2/Nce}$, is obtained from volume-specific O₂ flux, J_{V,O_2}
 234 [nmol·s⁻¹·L⁻¹], divided by the number concentration of cells, C_{Nce} [x·L⁻¹]. $C_{Nce} = N_{ce}·V^{-1}$, where N_{ce} is the
 235 number of cells in the chamber. O₂ flow is expressed in units of attomole (10⁻¹⁸ mol) of O₂ consumed
 236 per second per cell [amol·s⁻¹·cell⁻¹]²⁰, numerically equivalent to [pmol·s⁻¹·10⁻⁶ cells]. Generally, C_{NX} is
 237 the experimental number concentration of sample X . Several sample types are not countable objects,
 238 *e.g.*, tissue homogenate, in which case a sample-specific oxygen flow cannot be expressed.

239

240 **Size-specific flux: per sample size.** Mass-specific flux, $J_{O_2/mX}$ [mol·s⁻¹·kg⁻¹], expresses respiration
 241 normalized per mass of the sample. Mass-specific oxygen flux integrates the quality and density of
 242 mitochondria, and thus provides the appropriate normalization for evaluation of tissue performance.
 243 When studying isolated mitochondria and homogenized or permeabilized tissues and cells, $J_{O_2/mX}$ should
 244 be independent of the mass-concentration of the subsample obtained from the same tissue or cell culture.
 245 $I_{O_2/Nce}$ can be directly compared only between cells of identical size. To take into account differences in
 246 cell size, normalization is required to obtain cell size-specific flux, $J_{O_2/mce}$ or $J_{O_2/Vce}$ ²¹ (Fig. 3).

247

248 **Marker-specific flux: per mitochondrial content.** To evaluate differences in mitochondrial respiration
 249 independent of mitochondrial density, flux is normalized for structural or functional mt-elementary
 250 markers, *mtE*, expressed in marker-specific mt-elementary units [mtEU] (Fig. 3). For example, citrate
 251 synthase (CS) activity is a frequently applied functional *mtE* expressed in international units, IU
 252 [μmol·min⁻¹] (1 IU of CS forms 1 μmol of citrate per min; although the SI unit [nmol·s⁻¹] would be
 253 preferable). Then the mtEU is taken as [μmol·min⁻¹] or [nmol·s⁻¹]. Volume-specific oxygen flux, J_{V,O_2}
 254 [pmol·s⁻¹·mL⁻¹], is divided by CS activity expressed per chamber volume [mtEU·mL⁻¹], to obtain marker-
 255 specific respiratory flux, $J_{O_2/mtE}$ [pmol·s⁻¹·mtEU⁻¹]. Alternatively, $J_{O_2/mtE}$ is calculated from tissue mass-
 256 specific flux of permeabilized muscle fibers, $J_{O_2/m}$ [pmol O₂·s⁻¹·mg⁻¹], divided by tissue mass-specific
 257 CS activity [mtEU·mg⁻¹]. $J_{O_2/mtE}$ is independent of mitochondrial density. If the respirometric and
 258 enzymatic assays are performed at an identical temperature, OXPHOS- or ET-capacity can be compared
 259 with the capacity of CS as a regulatory enzyme in the tricarboxylic acid (TCA) cycle, which is of interest
 260 in the context of metabolic flux control.

261 One cannot assume that quantitative changes in various markers — such as CS activity, other
 262 mitochondrial enzyme activities or protein content — necessarily occur in parallel with one another²².
 263 It should be established that the marker chosen is not selectively altered by the compared trait or
 264 treatment. In conclusion, the normalization must reflect the question under investigation. On the other
 265 hand, the goal of combining results across projects and institutions requires standardization of
 266 normalization for entry into a databank.

267 Comparable to the concept of the respiratory acceptor control ratio, $RCR = \text{State 3}/\text{State 4}$,⁹ the
 268 most readily applied normalization is that of flux control ratios and flux control factors^{8,16}. Then, instead
 269 of a specific mt-enzyme activity, the respiratory activity in a reference state serves as the *mtE*, yielding
 270 a dimensionless ratio of two fluxes measured consecutively in the same respirometric titration protocol.
 271 Selection of the state of maximum flux in a protocol as the reference state — *e.g.*, ET-state in *L/E* and
 272 *P/E* flux control ratios¹⁶ — has the advantages of: (1) elimination of experimental variability in
 273 additional measurements, such as determination of enzyme activity or tissue mass; (2) statistically
 274 validated linearization of the response in the range of 0 to 1; and (3) consideration of maximum flux for
 275 integrating a large number of metabolic steps in the OXPHOS- or ET-pathways. This reduces the risk

276 of selecting a functional marker that is specifically altered by the treatment or pathology, yet increases
 277 the chance that the highly integrative pathway is affected, *e.g.*, the OXPHOS- rather than ET-pathway
 278 in case of an enzymatic defect in the phosphorylation-pathway. In this case, additional information can
 279 be obtained by reporting flux control ratios based on a reference state that indicates stable tissue mass-
 280 specific flux.

281

282 Conclusions

283

284 Clarity of concepts on mitochondrial respiratory control can serve as a gateway to better diagnose
 285 mitochondrial respiratory adaptations and defects linked to genetic variation, age-related health risks,
 286 sex-specific mitochondrial performance, lifestyle with its effects on degenerative diseases, and thermal
 287 and chemical environment. The challenges of measuring mitochondrial respiratory flux are matched by
 288 those of normalization: We distinguish between (1) the instrumental *system* or *chamber* with volume V
 289 and mass m defined by the system boundaries, and (2) the *sample* or *objects* with volume V_X and mass
 290 m_X that are enclosed in the instrumental chamber. Metabolic O_2 flow per countable object increases as
 291 the size of the object is increased. This confounding factor is eliminated by expressing respiration as
 292 mass-specific or cell volume-specific O_2 flux. The present recommendations on coupling control states
 293 and respiratory rates are focused on studies using mitochondrial preparations. Terms and symbols are
 294 summarized in Tab. 4. These need to be complemented by considerations on pathway control of
 295 mitochondrial respiration^{7,8,23}, respiratory states and rates in living cells, respiratory flux control ratios,
 296 and harmonization of experimental procedures. The present perspective is extended in a more detailed
 297 overview on quantitative mitochondrial physiology²⁴.

298

299 References

300

- 301 1. Cohen, E. R. et al. *IUPAC Green Book, 3rd Edition, 2nd Printing, IUPAC & RSC Publishing, Cambridge*
 302 (2008).
- 303 2. Gnaiger, E. *Pure Appl Chem* **65**, 1983-2002 (1993).
- 304 3. Beard, D. A. *PLoS Comput Biol* **1**, e36 (2005).
- 305 4. Mitchell, P. *Nature* **191**, 144-148 (1961).
- 306 5. Mitchell, P. *Biochim Biophys Acta Bioenergetics* **1807**, 1507-1538 (2011).
- 307 6. Schmitt, S. et al. *Anal Biochem* **443**, 66-74 (2013).
- 308 7. Doerrier, C. et al. *Methods Mol Biol* **1782**, 31-70 (2018).
- 309 8. §Gnaiger, E. *Bioenerg Commun* **2020.2**, doi:10.26124/bec:2020-0002.v1 (2020).
- 310 9. Chance, B. & Williams, G. R. *J Biol Chem* **217**, 383-393 (1955).
- 311 10. Schneider, T. D. *IEEE Eng Med Biol Mag* **25**, 30-33 (2006).
- 312 11. Gnaiger, E. *Respir Physiol* **128**, 277-297 (2001).
- 313 12. Watt, I. N. et al. *Proc Natl Acad Sci U S A* **107**, 16823-16827 (2010).
- 314 13. Németh, B. et al. *FASEB J* **30**, 286-300 (2016).
- 315 14. Fell, D. *Understanding the control of metabolism. Portland Press* (1997).
- 316 15. Chance, B. & Williams, G. R. *J Biol Chem* **217**, 409-427 (1955).
- 317 16. Gnaiger, E. *Int J Biochem Cell Biol* **41**, 1837-1845 (2009).
- 318 17. Miller, G. A. *The science of words. Scientific American Library New York* (1991).
- 319 18. Forstner, H. & Gnaiger, E. In: *Polarographic Oxygen Sensors. Aquatic and Physiological Applications.*
 320 *Gnaiger, E. & Forstner, H. (eds), Springer, Berlin, Heidelberg, New York, 321-333* (1983).
- 321 19. Chance, B. & Williams, G. R. *Adv Enzymol Relat Subj Biochem* **17**, 65-134 (1956).
- 322 20. Wagner, B. A., Venkataraman, S. & Buettner, G. R. *Free Radic Biol Med* **51**, 700-712 (2011).
- 323 21. Renner, K. et al. *Biochim Biophys Acta* **1642**, 115-123 (2003).
- 324 22. Drahotka, Z. et al. *Physiol Res* **53**, 119-122 (2004).
- 325 23. Schöpf, B. et al. *Nat Commun* **11**, 1487 (2020).
- 326 24. §Gnaiger, E. et al. *Bioenerg Commun* **2020.1**, doi:10.26124/bec:2020-0001.v1 (2020).
- 327 25. Canton, M. et al. *Biochem J* **310**, 477-481 (1995).
- 328 26. Rich, P. R. *Encyclopedia Biol Chem* **1**, 467-472 (2013).
- 329 27. Lemieux, H., Blier, P. U. & Gnaiger, E. *Sci Rep* **7**, 2840 (2017).

330

331 § To be released with DOI until acceptance by *Nat Metab*

332 At present:

333 8. Gnaiger, E. *Mitochondr Physiol Network 19.12. Oroboros MiPNet Publications, Innsbruck* (2014).

334 24. Gnaiger, E. et al. *MitoFit Preprint Arch* doi:10.26124/mitofit:190001.v6 (2019).

335
336 ***Authors (MitoEAGLE Task Group):** Gnaiger Erich, Aasander Frostner Eleonor, Abdul Karim
337 Norwahidah, Abdel-Rahman Engy Ali, Abumrad Nada A, Acuna-Castroviejo Dario, Adiele Reginald
338 C, Ahn Bumsoo, Alencar Mayke Bezerra, Ali Sameh S, Almeida Angeles, Alton Lesley, Alves Marco
339 G, Amati Francesca, Amoedo Nivea Dias, Amorim Ricardo, Anderson Ethan J, Andreadou Ioanna,
340 Antunes Diana, Arago Marc, Aral Cenk, Arandarcikaite Odeta, Arias-Reyes Christian, Armand Anne-
341 Sophie, Arnould Thierry, Avram Vlad F, Axelrod Christopher L, Bailey Damian M, Bairam Aida,
342 Bajpeyi Sudip, Bajzikova Martina, Bakker Barbara M, Banni Aml, Bardal Tora, Barlow J, Bastos
343 Sant'Anna Silva Ana Carolina, Batterson Philip M, Battino Maurizio, Bazil Jason N, Beard Daniel A,
344 Bednarczyk Piotr, Beleza Jorge, Bello Fiona, Ben-Shachar Dorit, Bento Guida Jose Freitas, Bergdahl
345 Andreas, Berge Rolf K, Bergmeister Lisa, Bernardi Paolo, Berridge Michael V, Bettinazzi Stefano,
346 Bishop David J, Blier Pierre U, Blindheim Dan Filip, Boardman Neoma T, Boetker Hans Erik, Borchard
347 Sabine, Boros Mihaly, Boersheim Elisabet, Borrás Consuelo, Borutaite Vilma, Botella Javier, Bouillaud
348 Frederic, Bouitbir Jamal, Boushel Robert C, Bovard Josh, Bravo-Sagua Roberto, Breton Sophie, Brown
349 David A, Brown Guy C, Brown Robert Andrew, Brozinick Joseph T, Buettner Garry R, Burtscher
350 Johannes, Bustos Matilde, Calabria Elisa, Calbet Jose AL, Calzia Enrico, Cannon Daniel T, Cano
351 Sanchez Maria Consolacion, Canto Alvarez Carles, Cardinale Daniele A, Cardoso Luiza HD, Carvalho
352 Eugenia, Casado Pinna Marta, Cassar Samantha, Castelo Rueda Maria Paulina, Castilho Roger F,
353 Cavalcanti-de-Albuquerque Joao Paulo, Cecatto Cristiane, Celen Murat C, Cervinkova Zuzana, Chabi
354 Beatrice, Chakrabarti Lisa, Chakrabarti Sasanka, Chaurasia Bhagirath, Chen Quan, Chicco Adam J,
355 Chinopoulos Christos, Chowdhury Subir Kumar, Cizmarova Beata, Clementi Emilio, Coen Paul M,
356 Cohen Bruce H, Coker Robert H, Collin-Chenot Anne, Coughlan Melinda T, Coxito Pedro, Crisostomo
357 Luis, Crispim Marcell, Crossland Hannah, Dahdah Norma Ramon, Dalgaard Louise T, Dambrova
358 Maija, Danhelovska Tereza, Darveau Charles-A, Darwin Paula M, Das Anibh Martin, Dash Ranjan K,
359 Davidova Eliska, Davis Michael S, Dayanidhi Sudarshan, De Bem Andreza Fabro, De Goede Paul, De
360 Palma Clara, De Pinto Vito, Dela Flemming, Dembinska-Kiec Aldona, Detraux Damian, Devaux Yvan,
361 Di Marcello Marco, Di Paola Floriana Jessica, Dias Candida, Dias Tania R, Diederich Marc, Distefano
362 Giovanna, Djafarzadeh Siamak, Doermann Niklas, Doerrier Carolina, Dong Lan-Feng, Donnelly Chris,
363 Drahota Zdenek, Duarte Filipe Valente, Dubouchaud Herve, Duchon Michael R, Dumas Jean-Francois,
364 Durham William J, Dymkowska Dorota, Dyrstad Sissel E, Dyson Alex, Dzialowski Edward M, Eaton
365 Simon, Ehinger Johannes K, Elmer Eskil, Endlicher Rene, Engin Ayse Basak, Escames Germaine,
366 Evinova Andrea, Ezrova Zuzana, Falk Marni J, Fell David A, Ferdinandy Peter, Ferko Miroslav,
367 Fernandez-Vizarrá Erika, Ferreira Julio Cesar B, Ferreira Rita Maria P, Ferri Alessandra, Fessel Joshua
368 Patrick, Festuccia William T, Filipovska Aleksandra, Fisar Zdenek, Fischer Christine, Fischer Michael
369 J, Fisher Gordon, Fisher Joshua J, Fontanesi Flavia, Ford Ellen, Fornaro Mara, Fuertes Agudo Marina,
370 Fulton Montana, Galina Antonio, Galkin Alexander, Gallee Leon, Galli Gina L J, Gama Perez Pau, Gan
371 Zhenji, Ganetzky Rebecca, Gao Yun, Garcia Geovana S, Garcia-Rivas Gerardo, Garcia-Roves Pablo
372 Miguel, Garcia-Souza Luiz F, Garlid Keith D, Garrabou Gloria, Garten Antje, Gastaldelli Amalia,
373 Gayen Jiaur, Genders Amanda J, Genova Maria Luisa, Giampieri Francesca, Giovarelli Matteo, Glatz
374 Jan FC, Goikoetxea Usandizaga Naroa, Goncalo Teixeira da Silva Rui, Goncalves Debora Farina,
375 Gonzalez-Armenta Jenny L, Gonzalez-Franquesa Alba, Gonzalez-Freire Marta, Gonzalo Hugo,
376 Goodpaster Bret H, Gorr Thomas A, Gourlay Campbell W, Grams Bente, Granata Cesare, Grefte
377 Sander, Grilo Luis, Guarch Meritxell Espino, Gueguen Naig, Gumeni Sentiljana, Haas Clarissa, Haavik
378 Jan, Hachmo Yafit, Haendeler Judith, Haider Markus, Hajrulahovic Anesa, Hamann Andrea, Han Jin,
379 Han Woo Hyun, Hancock Chad R, Hand Steven C, Handl Jiri, Hansikova Hana, Hardee Justin P,
380 Hargreaves Iain P, Harper Mary-Ellen, Harrison David K, Hassan Hazirah, Hatokova Zuzana,
381 Hausenloy Derek J, Heales Simon JR, Hecker Matthias, Heiestad Christina, Hellgren Kim T, Henrique
382 Alexandrino, Hepple Russell T, Hernansanz-Agustin Pablo, Hewakapuge Sudinna, Hickey Anthony J,
383 Ho Dieu Hien, Hoehn Kyle L, Hoel Fredrik, Holland Olivia J, Holloway Graham P, Holzner Lorenz,
384 Hoppel Charles L, Hoppel Florian, Hoppeler Hans, Houstek Josef, Huete-Ortega Maria, Hyrossova
385 Petra, Iglesias-Gonzalez Javier, Irving Brian A, Isola Raffaella, Iyer Shilpa, Jackson Christopher
386 Benjamin, Jadiya Pooja, Jana Prado Fabian, Jandeleit-Dahm Karin, Jang David H, Jang Young Charles,
387 Janowska Joanna, Jansen Kirsten M, Jansen-Duerr Pidder, Jansone Baiba, Jarmuskiewicz Wieslawa,
388 Jaskiewicz Anna, Jaspers Richard T, Jedlicka Jan, Jerome Estaquier, Jespersen Nichlas Riise, Jha Rajan
389 Kumar, Jones John G, Joseph Vincent, Jurczak Michael J, Jurk Diana, Jusic Amela, Kaambre Tuuli,
390 Kaczor Jan Jacek, Kainulainen Heikki, Kampa Rafal Pawel, Kandel Sunil Mani, Kane Daniel A,

391 Kapferer Werner, Kapnick Senta, Kappler Lisa, Karabatsiakos Alexander, Karavaeva Iuliia,
392 Karkucinska-Wieckowska Agnieszka, Kaur Sarbjot, Keijer Jaap, Keller Markus A, Keppner Gloria,
393 Khamoui Andy V, Kidere Dita, Kilbaugh Todd, Kim Hyoung Kyu, Kim Julian KS, Kimoloi Sammy,
394 Klepinin Aleksandr, Klepinina Lyudmila, Klingenspor Martin, Klocker Helmut, Kolassa Iris, Komlodi
395 Timea, Koopman Werner JH, Kopitar-Jerala Natasa, Kowaltowski Alicia J, Kozlov Andrey V, Krajcova
396 Adela, Krako Jakovljevic Nina, Kristal Bruce S, Krycer James R, Kuang Jujiao, Kucera Otto, Kuka
397 Janis, Kwak Hyo Bum, Kwast Kurt E, Kwon Oh Sung, Laasmaa Martin, Labieniec-Watala Magdalena,
398 Lagarrigue Sylviane, Lai Nicola, Lalic Nebojsa M, Land John M, Lane Nick, Laner Verena, Lanza Ian
399 R, Laouafa Sofien, Laranjinha Joao, Larsen Steen, Larsen Terje S, Lavery Gareth G, Lazou Antigone,
400 Ledo Ana Margarida, Lee Hong Kyu, Leeuwenburgh Christiaan, Lehti Maarit, Lemieux Helene, Lenaz
401 Giorgio, Lerfall Joergen, Li Pingan Andy, Li Puma Lance, Liang Liping, Liepins Edgars, Lin Chien-Te,
402 Liu Jiankang, Lopez Garcia Luis Carlos, Lucchinetti Eliana, Ma Tao, Macedo Maria Paula, Machado
403 Ivo F, Maciej Sarah, MacMillan-Crow Lee Ann, Magalhaes Jose, Magri Andrea, Majtnerova Pavlina,
404 Makarova Elina, Makrecka-Kuka Marina, Malik Afshan N, Marcouiller Francois, Markova Michaela,
405 Markovic Ivanka, Martin Daniel S, Martins Ana Dias, Martins Joao D, Maseko Tumisang Edward,
406 Maull Felicia, Mazat Jean-Pierre, McKenna Helen T, McKenzie Matthew, McMillan Duncan GG,
407 Mendham Amy, Menze Michael A, Mercer John R, Merz Tamara, Messina Angelina, Meszaros Andras,
408 Methner Axel, Michalak Slawomir, Mila Guasch Maria, Minuzzi Luciele M, Moellering Douglas R,
409 Moiso Nicoleta, Molina Anthony JA, Montaigne David, Moore Anthony L, Moore Christy, Moreau
410 Kerrie, Moreira Bruno P, Moreno-Sanchez Rafael, Mracek Tomas, Muccini Anna Maria, Munro Daniel,
411 Muntane Jordi, Muntean Danina M, Murray Andrew James, Musiol Eva, Nabben Miranda, Nair K
412 Sreekumaran, Nehlin Jan O, Nemecek Michal, Nesci Salvatore, Neuffer P Darrell, Neuzil Jiri, Nevriere
413 Remi, Newsom Sean A, Norman Jennifer, Nozickova Katerina, Nunes Sara, O'Brien Kristin, O'Brien
414 Katie A, O'Gorman Donal, Olgar Yusuf, Oliveira Ben, Oliveira Jorge, Oliveira Marcus F, Oliveira
415 Marcos Tulio, Oliveira Pedro Fontes, Oliveira Paulo J, Olsen Rolf Erik, Orynbayeva Zulfiya, Osiewacz
416 Heinz D, Paez Hector, Pak Youngmi Kim, Pallotta Maria Luigia, Palmeira Carlos, Parajuli Nirmala,
417 Passos Joao F, Passrigger Manuela, Patel Hemal H, Pavlova Nadia, Pavlovic Kasja, Pecina Petr,
418 Pedersen Tina M, Perales Jose Carles, Pereira da Silva Grilo da Silva Filomena, Pereira Rita, Pereira
419 Susana P, Perez Valencia Juan Alberto, Perks Kara L, Pesta Dominik, Petit Patrice X, Pettersen Nitschke
420 Ina Katrine, Pichaud Nicolas, Pichler Irene, Piel Sarah, Pietka Terri A, Pinho Sonia A, Pino Maria F,
421 Pirkmajer Sergej, Place Nicolas, Plangger Mario, Porter Craig, Porter Richard K, Pregoica Ines, Prigione
422 Alessandro, Procaccio Vincent, Prochownik Edward V, Prola Alexandre, Pulinilkunnil Thomas,
423 Puskarich Michael A, Puurand Marju, Radenkovic Filip, Ramzan Rabia, Rattan Suresh IS, Reano
424 Simone, Reboredo-Rodriguez Patricia, Rees Bernard B, Renner-Sattler Kathrin, Rial Eduardo,
425 Robinson Matthew M, Roden Michael, Rodrigues Ana Sofia, Rodriguez Enrique, Rodriguez-Enriquez
426 Sara, Roesland Gro Vatne, Rohlena Jakub, Rolo Anabela Pinto, Ropelle Eduardo R, Roshanravan
427 Baback, Rossignol Rodrigue, Rossiter Harry B, Rousar Tomas, Rubelj Ivica, Rybacka-Mossakowska
428 Joanna, Saada Reisch Ann, Safaei Zahra, Salin Karine, Salvadeo Desy, Sandi Carmen, Saner Nicholas,
429 Santos Diana, Sanz Alberto, Sardao Vilma, Sarlak Saharnaz, Sazanov Leonid A, Scaife Paula, Scatena
430 Roberto, Schartner Melanie, Scheibye-Knudsen Morten, Schilling Jan M, Schlattner Uwe, Schmitt
431 Sabine, Schneider Gasser Edith Mariane, Schoenfeld Peter, Schots Pauke C, Schulz Rainer, Schwarzer
432 Christoph, Scott Graham R, Selman Colin, Sendon Pamela Marie, Shabalina Irina G, Sharma Pushpa,
433 Sharma Vipin, Shevchuk Igor, Shirazi Reza, Shiroma Jonathan G, Siewiera Karolina, Silber Ariel M,
434 Silva Ana Maria, Sims Carrie A, Singer Dominique, Singh Brijesh Kumar, Skolik Robert A, Smenes
435 Benedikte Therese, Smith James, Soares Felix Alexandre Antunes, Sobotka Ondrej, Sokolova Inna,
436 Solesio Maria E, Soliz Jorge, Sommer Natascha, Sonkar Vijay K, Sova Marina, Sowton Alice P,
437 Sparagna Genevieve C, Sparks Lauren M, Spinazzi Marco, Stankova Pavla, Starr Jonathan, Stary Creed,
438 Stefan Eduard, Stelfa Gundega, Stepto Nigel K, Stevanovic Jelena, Stiban Johnny, Stier Antoine,
439 Stocker Roland, Storder Julie, Sumbalova Zuzana, Suomalainen Anu, Suravajhala Prashanth, Svalbe
440 Baiba, Swerdlow Russell H, Swiniuch Daria, Szabo Ildiko, Szewczyk Adam, Szibor Marten, Tanaka
441 Masashi, Tandler Bernard, Tarnopolsky Mark A, Tausan Daniel, Tavernarakis Nektarios, Teodoro Joao
442 Soeiro, Tepp Kersti, Thakkar Himani, Thapa Maheshwor, Thyfault John P, Tomar Dhanendra, Ton
443 Riccardo, Torp May-Kristin, Torres-Quesada Omar, Towheed Atif, Treberg Jason R, Tretter Laszlo,
444 Trewin Adam J, Trifunovic Aleksandra, Trivigno Catherine, Tronstad Karl Johan, Trougakos Ioannis
445 P, Truu Laura, Tuncay Erkan, Turan Belma, Tyrrell Daniel J, Urban Tomas, Urner Sofia, Valentine
446 Joseph Marco, Van Bergen Nicole J, Van der Ende Miranda, Varricchio Frederick, Vaupel Peter, Vella

447 Joanna, Vendelin Marko, Vercesi Anibal E, Verdaguer Ignasi Bofill, Vernerova Andrea, Victor Victor
448 Manuel, Vieira Ligo Teixeira Camila, Vidimce Josif, Viel Christian, Vieyra Adalberto, Vilks Karlis,
449 Villena Josep A, Vincent Vinnyfred, Vinogradov Andrey D, Viscomi Carlo, Vitorino Rui Miguel
450 Pinheiro, Vlachaki Walker Julia, Vogt Sebastian, Volani Chiara, Volska Kristine, Votion Dominique-
451 Marie, Vujacic-Mirski Ksenija, Wagner Brett A, Ward Marie Louise, Warnsmann Verena, Wasserman
452 David H, Watala Cezary, Wei Yau-Huei, Weinberger Klaus M, Weissig Volkmar, White Sarah Haverty,
453 Whitfield Jamie, Wickert Anika, Wieckowski Mariusz R, Wiesner Rudolf J, Williams Caroline M,
454 Winwood-Smith Hugh, Wohlgemuth Stephanie E, Wohlwend Martin, Wolff Jonci Nikolai, Wrutniak-
455 Cabello Chantal, Wuest Rob CI, Yokota Takashi, Zablocki Krzysztof, Zanon Alessandra, Zanou
456 Nadege, Zaugg Kathrin, Zaugg Michael, Zdrzilova Lucie, Zhang Yong, Zhang Yizhu, Zikova Alena,
457 Zischka Hans, Zorzano Antonio, Zujovic Tijana, Zvejniece Liga

Affiliations:

458 https://www.bioenergetics-communications.org/index.php/BEC2020.1_doi10.26124bec2020-0001.v1
459

460

461 **Acknowledgements**

462 We thank Beno M for management assistance, and Rich PR for valuable discussions. This publication
463 is based upon work from COST Action CA15203 MitoEAGLE, supported by COST (European
464 Cooperation in Science and Technology), in cooperation with COST Actions CA16225 EU-
465 CARDIOPROTECTION and CA17129 CardioRNA, and K-Regio project MitoFit funded by the
466 Tyrolian Government.

467

468 **Author contributions**

469 This manuscript developed as an open invitation to scientists and students to join as coauthors in the
470 bottom-up spirit of COST, based on a first draft written by the corresponding author, who integrated
471 coauthor contributions in a sequence of Open Access versions. Coauthors contributed to the scope and
472 quality of the manuscript, may have focused on a particular section, and are listed in alphabetical order.
473 Coauthors confirm that they have read the final manuscript and agree to implement the
474 recommendations into future manuscripts, presentations and teaching materials.

475

476 **Competing interests**

477 E.G. is founder and CEO of Oroboros Instruments, Innsbruck, Austria. The other authors declare no
478 competing financial interests.

479

480 **Tables**

481

482 **Table 1 | Coupling control states and rates, and residual oxygen consumption in**
 483 **mitochondrial preparations.** Respiration- and phosphorylation-flux, J_{kO_2} and J_{P} , are rates,
 484 characteristic of a state in conjunction with the protonmotive force, pmF . Coupling states are
 485 established at kinetically-saturating concentrations of fuel substrates and O_2 .
 486

| State | Rate | J_{kO_2} | J_{P} | pmF | Inducing factors | Limiting factors |
|--------|----------|---|----------------|-------|---|---|
| LEAK | L | low, cation leak-dependent respiration | 0 | max. | back-flux of cations including proton leak, proton slip | $J_{\text{P}} = 0$: (1) without ADP, $L(n)$; (2) max. ATP/ADP ratio, $L(T)$; or (3) inhibition of the phosphorylation-pathway, $L(O_{my})$ |
| OXPHOS | P | high, ADP-stimulated respiration, OXPHOS-capacity | max. | high | kinetically-saturating [ADP] and $[P_i]$ | J_{P} by phosphorylation-pathway capacity; or J_{kO_2} by ET-capacity |
| ET | E | max., noncoupled respiration, ET-capacity | 0 | low | optimal external uncoupler concentration for max. $J_{\text{O}_2, E}$ | J_{kO_2} by ET-capacity |
| ROX | R_{ox} | min., residual O_2 consumption | 0 | 0 | $J_{\text{O}_2, R_{ox}}$ in non-ET-pathway oxidation reactions | inhibition of all ET-pathways; or absence of fuel substrates |

487

488
489**Table 2 | Terms on respiratory coupling and uncoupling**

| Term | J_{kO_2} | $P \gg O_2$ | Notes | |
|----------------------------------|-----------------------|-------------|-------|--|
| intrinsic, no protonophore added | uncoupled | L | 0 | non-phosphorylating LEAK-respiration (Fig. 2) |
| | proton leak-uncoupled | | 0 | component of L , H^+ diffusion across the mtIM (Fig. 2b-d) |
| | inducibly uncoupled | | 0 | by UCP1 or cation (<i>e.g.</i> , Ca^{2+}) cycling; strongly stimulated by permeability transition (mtPT); experimentally induced by valinomycin in the presence of K^+ |
| | decoupled | | 0 | component of L , proton slip when protons are effectively not pumped in the redox proton pumps CI, CIII and CIV or are not driving phosphorylation (F-ATPase) ²⁵ (Fig. 2b-d) |
| | loosely coupled | | 0 | component of L , lower coupling due to superoxide formation and bypass of proton pumps by electron leak with univalent reduction of O_2 to superoxide ($O_2^{\cdot-}$; superoxide anion radical) |
| | dyscoupled | | 0 | mitochondrial dysfunction due to pathologically, toxicologically, environmentally increased uncoupling |
| noncoupled | E | | 0 | ET-capacity, non-phosphorylating respiration stimulated to maximum flux at optimum exogenous protonophore concentration (Fig. 2d) |
| well-coupled | P | | high | OXPPOS-capacity , phosphorylating respiration with an intrinsic LEAK component (Fig. 2c) |
| fully coupled | $P - L$ | | max. | OXPPOS-capacity corrected for LEAK-respiration (Fig. 2a) |
| acoupled | | | 0 | electron transfer in mitochondrial fragments without vectorial proton translocation upon loss of vesicular (compartmental) integrity |

490
491

492 **Table 3 | Conversion of units**

493 **a.** Conversion of O_2 flow, I_{O_2} , to SI units (e^- is the number of electrons or reducing
494 equivalents)

| 1 Unit | | Multiplication factor | SI-unit |
|--|---------------------|-----------------------|--------------------------------------|
| ng.atom O·s ⁻¹ | (2 e ⁻) | 0.5 | nmol O ₂ ·s ⁻¹ |
| ng.atom O·min ⁻¹ | (2 e ⁻) | 8.33 | pmol O ₂ ·s ⁻¹ |
| natom O·min ⁻¹ | (2 e ⁻) | 8.33 | pmol O ₂ ·s ⁻¹ |
| nmol O ₂ ·min ⁻¹ | (4 e ⁻) | 16.67 | pmol O ₂ ·s ⁻¹ |
| nmol O ₂ ·h ⁻¹ | (4 e ⁻) | 0.2778 | pmol O ₂ ·s ⁻¹ |

495

496 **b.** Conversion of units with preservation of numerical values
497

| Name | Frequently used unit | Equivalent unit | Notes |
|--|--|--|-------|
| volume-specific flux, J_{V,O_2} | pmol·s ⁻¹ ·mL ⁻¹ | nmol·s ⁻¹ ·L ⁻¹ | 1 |
| | mmol·s ⁻¹ ·L ⁻¹ | mol·s ⁻¹ ·m ⁻³ | |
| cell-specific flow, $I_{O_2/N_{ce}}$ | pmol·s ⁻¹ ·10 ⁻⁶ cells | amol·s ⁻¹ ·cell ⁻¹ | 2 |
| | pmol·s ⁻¹ ·10 ⁻⁹ cells | zmol·s ⁻¹ ·cell ⁻¹ | 3 |
| cell number concentration, $C_{N_{ce}}$ | 10 ⁶ cells·mL ⁻¹ | 10 ⁹ cells·L ⁻¹ | |
| mitochondrial protein concentration, C_{mtE} | 0.1 mg·mL ⁻¹ | 0.1 g·L ⁻¹ | |
| mass-specific flux, $J_{O_2/m}$ | pmol·s ⁻¹ ·mg ⁻¹ | nmol·s ⁻¹ ·g ⁻¹ | 4 |
| volume | 1,000 L | m ³ (1,000 kg) | |
| | L | dm ³ (kg) | |
| | mL | cm ³ (g) | |
| | μL | mm ³ (mg) | |
| | fL | μm ³ (pg) | 5 |
| amount of substance concentration | M = mol·L ⁻¹ | mol·dm ⁻³ | |

498 1 pmol: picomole = 10⁻¹² mol499 2 amol: attomole = 10⁻¹⁸ mol500 3 zmol: zeptomole = 10⁻²¹ mol

501

4 nmol: nanomole = 10⁻⁹ mol5 fL: femtolitre = 10⁻¹⁵ L

Table 4 | Terms, symbols, and units. SI base units are used, except for the liter [L = dm³]

| Term | Symbol | Unit | Links and comments |
|---|----------------------------------|--|---|
| alternative quinol oxidase | AOX | | Fig. 1b |
| adenosine diphosphate | ADP | | Tab. 1; Fig. 1 and 2 |
| adenosine triphosphate | ATP | | Tab. 1; Fig. 1 and 2 |
| ATP hydrolysis ATP→ADP | P _« | | Fig. 2b,c |
| catabolic reaction | k | | Tab. 1 and 2; Fig. 1 and 2 |
| catabolic respiration | J_{kO_2} | <i>varies</i> | Fig 1c, Fig. 2b-d |
| cell concentration (number [x]) | C_{Nce} | [x·L ⁻¹] | for normalization of rate |
| coenzyme Q-junction | Q-junction | | Fig. 1b |
| electron transfer Complexes | CI to CIV | | Fig. 1b; F ₁ F ₀ -ATPase is not an ET- but a phosphorylation-pathway Complex, hence the term Complex V should not be used |
| electron transfer, state | ET | | Tab. 1; Fig. 2a (State 3u) |
| electron transfer system | ETS | | Fig. 1b |
| ET-capacity | E | <i>varies</i> | Tab. 1; Fig. 2a,d; rate |
| ET-excess capacity | $E-P$ | <i>varies</i> | Fig. 2a |
| flow | I | [mol·s ⁻¹] | Fig. 3; extensive quantity |
| flux | J | <i>varies</i> | Fig. 3; size-specific quantity |
| inorganic phosphate | P _i | | Fig. 1d |
| inorganic phosphate carrier | PiC | | Fig. 1d |
| LEAK-state | LEAK | | Tab. 1; Fig. 2a (compare State 4) |
| LEAK-respiration | L | <i>varies</i> | rate; Tab. 1; Fig. 2a,b |
| mass of sample or object X | m_X or m_{NX} | [kg] or [kg·x ⁻¹] | Fig. 3 |
| mass, dry mass | m_d | [kg] or [kg·x ⁻¹] | (dry weight) |
| mass, wet mass | m_w | [kg] or [kg·x ⁻¹] | (wet weight) |
| mitochondria or mitochondrial | mt | | compare mtDNA |
| mitochondrial elementary marker | mtE | [mtEU] | Fig. 3; quantity of mt-marker |
| mitochondrial elementary unit | mtEU | <i>varies</i> | Fig. 3; specific units for mt-marker |
| mitochondrial inner membrane | mtIM | | Fig. 1 (MIM) |
| mitochondrial outer membrane | mtOM | | Fig. 1 (MOM) |
| NADH-junction | N-junction | | Fig. 1b |
| number concentration of X | C_{NX} | [x·L ⁻¹] | for normalization of rate |
| number format | \underline{N} | [x] | Fig. 3 |
| number of cells | N_{ce} | [x] | for normalization of rate |
| number of entities X | N_X | [x] | Fig. 3; for normalization of rate |
| O ₂ concentration | $c_{O_2} = n_{O_2} \cdot V^{-1}$ | [mol·L ⁻¹] | [O ₂] |
| O ₂ flow per countable object | $I_{O_2/NX}$ | [mol·s ⁻¹ ·x ⁻¹] | Fig. 3 |
| O ₂ flow per chamber | I_{O_2} | [mol·s ⁻¹] | Fig. 3 |
| O ₂ flux, in reaction r | J_{rO_2} | <i>varies</i> | Fig. 1a |
| O ₂ flux, volume-specific | J_{V,O_2} | [mol·s ⁻¹ ·L ⁻¹] | Fig. 3; per volume of chamber |
| O ₂ flux, sample mass-specific | $J_{O_2/mX}$ | [mol·s ⁻¹ ·kg ⁻¹] | Fig. 3; specify dry or wet mass |
| oxidative phosphorylation | OXPHOS | | Fig. 1 |
| OXPHOS-state | OXPHOS | | Tab. 1; Fig. 2a (State 3 at kinetically-saturating [ADP] and [P _i]) |
| OXPHOS-capacity | P | <i>varies</i> | rate; Tab. 1; Fig. 2a,c |
| permeability transition | mtPT | | Tab. 2; MPT is widely used |
| phosphorylation flux ADP→ATP | $J_{P_»}$ | <i>varies</i> | Fig. 2b-d |
| phosphorylation of ADP to ATP | P _» | | Fig. 1 |
| P _» /O ₂ ratio | P _» /O ₂ | | mechanistic $Y_{P_»/O_2}$, calculated from pump stoichiometries; Fig. 1c |

| | | | | | |
|-----|---------------------------------------|-------------------|---------------------------|--|---------------------------------------|
| 559 | proton in the negative compartment | H^+_{neg} | | | Fig. 2b-d |
| 560 | proton in the positive compartment | H^+_{pos} | | | Fig. 1b,c; Fig. 2b-d |
| 561 | protonmotive flux to the negative | | | | |
| 562 | compartment | J_{mH+neg} | <i>varies</i> | | Fig. 2d,f |
| 563 | protonmotive flux to the positive | | | | |
| 564 | compartment | J_{mH+pos} | <i>varies</i> | | Fig. 2b,c,d |
| 565 | protonmotive force | pmF | [V] | | Figures 1, 2A and 4; Table 1 |
| 566 | rate of electron transfer in ET-state | E | <i>varies</i> | | Tab. 1; ET-capacity |
| 567 | rate of LEAK-respiration | L | <i>varies</i> | | Tab. 1; $L(n)$, $L(T)$, $L(O_{my})$ |
| 568 | rate of oxidative phosphorylation | P | <i>varies</i> | | Tab. 1; OXPHOS-capacity |
| 569 | rate of residual oxygen consumption | Rox | <i>varies</i> | | Tab. 1 |
| 570 | residual oxygen consumption, state | ROX | | | Tab. 1 |
| 571 | sample type | X | | | |
| 572 | substrate-uncoupler-inhibitor- | | | | |
| 573 | titration protocol | SUIT | | | |
| 574 | tricarboxylic acid cycle | TCA cycle | | | Fig. 1a |
| 575 | volume | V | [L] | | |
| 576 | volume format | \underline{V} | [L] | | Fig. 3 |
| 577 | volume of sample or object X | V_X or V_{MX} | [L] or $[L \cdot x^{-1}]$ | | Fig. 3 |
| 578 | | | | | |
| 579 | | | | | |

580 **Figures**

581





Fig. 1. | Respiration and oxidative phosphorylation (OXPHOS). (a) Cell respiration: uptake of small molecules and catabolism of macronutrients provide the mitochondrial fuel substrates (electron donors), which are oxidized with electron transfer to O₂ (electron acceptor). Dashed arrows indicate the connection between the redox proton pumps (respiratory Complexes CI, CIII and CIV) and the transmembrane protonmotive force, *pmF*. Coenzyme Q (Q) and the cytochromes *b*, *c*, and *aa₃* are redox systems of the mitochondrial inner membrane, mtIM. Glycerol-3-phosphate, Gp. (b) Mitochondrial respiration: The mitochondrial electron transfer system (ETS) is (1) fueled by diffusion and transport of substrates across the mitochondrial outer and inner membranes (mtOM and mtIM), and in addition consists of the (2) matrix-ETS, and (3) membrane-ETS. Electron transfer converges from dehydrogenases at the NADH-junction (N-junction), and from CI,

582
583
584
585
586
587
588
589
590
591
592
593

594 CII and electron transferring flavoprotein complex (CETF) at the Coenzyme Q-junction
595 (Q-junction). Unlabeled arrows converging at the Q-junction indicate additional ETS-
596 sections with electron entry into Q through Gp-dehydrogenase, dihydroorotate
597 dehydrogenase, proline dehydrogenase, choline dehydrogenase, and sulfide-ubiquinone
598 oxidoreductase. The dotted arrow indicates the branched pathway of oxygen consumption
599 by alternative quinol oxidase (AOX). ET-pathways are coupled to the phosphorylation-
600 pathway. The H^+_{pos}/O_2 ratio is the outward proton flux from the matrix space to the
601 positively (pos) charged vesicular compartment, divided by catabolic O_2 flux in the NADH-
602 pathway ²⁶. The H^+_{neg}/P_{\gg} ratio is the inward proton flux from the inter-membrane space to
603 the negatively (neg) charged matrix space, divided by phosphorylation flux of ADP to ATP.
604 These stoichiometries are not fixed because of ion leaks and proton slip. Modified from ref
605 27. **(c) OXPHOS-coupling:** The H^+ circuit couples O_2 flux through the catabolic ET-
606 pathway, J_{kO_2} , to flux through the phosphorylation-pathway of ADP to ATP, $J_{P_{\gg}}$.
607 **(d) Phosphorylation-pathway:** the proton pump F_1F_0 -ATPase (F-ATPase, ATP synthase),
608 adenine nucleotide translocase (ANT), and inorganic phosphate carrier (PiC). The H^+_{neg}/P_{\gg}
609 stoichiometry is the sum of the coupling stoichiometry in the F-ATPase reaction ($-2.7 H^+_{\text{pos}}$
610 from the positive intermembrane space, $2.7 H^+_{\text{neg}}$ to the matrix, *i.e.*, the negative
611 compartment) and the proton balance in the translocation of ADP^{3-} , ATP^{4-} and P_i^{2-} (negative
612 for substrates) ¹². Modified from ref 8.
613

614 **Fig. 2 | Respiratory states and**
 615 **rates. (a)** Four-compartment model
 616 of oxidative phosphorylation:
 617 respiratory states (ET, OXPHOS,
 618 LEAK) and corresponding rates (E ,
 619 P , L) are connected by the
 620 protonmotive force, pmF . (1) ET-
 621 capacity, E , is partitioned into (2)
 622 dissipative LEAK-respiration, L ,
 623 when the Gibbs energy change of
 624 catabolic O_2 flux is irreversibly lost,
 625 (3) net OXPHOS-capacity, $P-L$, with
 626 partial conservation of the capacity
 627 to perform work, and (4) the ET-
 628 excess capacity, $E-P$. (b) **LEAK-**
 629 **rate, L** : Oxidation only, since
 630 phosphorylation is arrested, $J_{P\gg} = 0$,
 631 and catabolic O_2 flux, $J_{kO_2,L}$, is
 632 controlled mainly by the proton
 633 leak and slip, $J_{mH^{+neg}}$ (motive,
 634 subscript m), at maximum
 635 protonmotive force. ATP may be
 636 hydrolyzed by ATPases, $J_{P\ll}$; then
 637 phosphorylation must be blocked.
 638 (c) **OXPHOS-rate, P** : Oxidation
 639 coupled to phosphorylation, $J_{P\gg}$,
 640 which is stimulated by
 641 kinetically-saturating [ADP] and
 642 [P_i], supported by a high
 643 protonmotive force maintained
 644 by pumping of protons to the
 645 positive compartment, $J_{mH^{+pos}}$. O_2
 646 flux, $J_{kO_2,P}$, is well-coupled at a
 647 $P\gg/O_2$ flux ratio of $J_{P\gg,P}/J_{O_2,P}$.
 648 Extramitochondrial ATPases may
 649 recycle ATP, $J_{P\ll}$. (d) **ET- rate, E** :
 650 Oxidation only, since
 651 phosphorylation is zero, $J_{P\gg} = 0$,
 652 at optimum exogenous uncoupler
 653 concentration when noncoupled
 654 respiration, $J_{kO_2,E}$, is maximum. The F_1F_0 -ATPase may hydrolyze ATP entering the
 655 mitochondria. Modified from ref 8.
 656



The F_1F_0 -ATPase may hydrolyze ATP entering the mitochondria. Modified from ref 8.

657 **Fig. 3 | Different meanings of**
 658 **rate: flow and flux dependent on**
 659 **normalization for sample or**
 660 **instrumental chamber.**

661 Fundamental distinction between
 662 metabolic rate related to the
 663 experimental sample (left) or to
 664 the instrumental chamber (right).
 665 Left: Results are expressed as
 666 mass-specific flux, J_{mX} , per mg
 667 protein, dry or wet mass. Cell
 668 volume, V_{ce} , may be used for
 669 normalization (volume-specific
 670 flux, J_{Vce}). Normalization per
 671 mitochondrial elementary marker,
 672 mtE , relies on determination of mt-
 673 markers expressed in various
 674 mitochondrial elementary units [mtEU]. Right: Flow per instrumental chamber, I , or flux per chamber
 675 volume, J_V , are reported for methodological reasons.
 676

